Shenwu Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shenwu Zhang has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
Zhonggui He
18 shared publications- Cong Luo
Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, PR China
14 shared publications Jin Sun
13 shared publicationsJianbin Shi
10 shared publicationsXinxin Sun
Department of Pharmaceutics Wuya College of Innovation Shenyang Pharmaceutical University Shenyang China
10 shared publicationsCong Luo
8 shared publications
Latest Publications
- 13 November 2026
- Published by Elsevier in Chinese Chemical Letters
Biomimetic microneedle platforms for immunomodulation in immune-mediated skin diseases
- 13 November 2026
- Published by Elsevier in Chinese Chemical Letters
Biomimetic microneedle platforms for immunomodulation in immune-mediated skin diseases
- 16 September 2026
- Published by Elsevier in Chinese Chemical Letters
A closed-loop ferroptosis-regulating hydrogel promotes diabetic wound healing
- 16 September 2026
- Published by Elsevier in Chinese Chemical Letters
A closed-loop ferroptosis-regulating hydrogel promotes diabetic wound healing
- 17 August 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15  (35)
PyroptosisâInducing Nanomedicine for Cancer Immunotherapy: Mechanisms and Emerging Strategies
Cancer immunotherapy has revolutionized oncologic treatment, yet its efficacy remains constrained by tumor immune evasion and the immunosuppressive tumor microenvironment. Addressing these multifaceted barriers calls for strategies that can both eliminate cancer cells and simultaneously amplify antitumor immunity. Pyroptosis, a lytic and highly immunogenic form of programmed cell death mediated by gasdermin proteins, has recently emerged as a compelling approach to reprogram the tumor immune landscape. By releasing abundant damageâassociated molecular patterns and proâinflammatory cytokines, pyroptosis not only destroys tumor cells but also promotes antigen presentation and robust localâtoâsystemic immune responses. With the rapid advancement of nanotechnology, pyroptosisâengineered nanomedicine has gained increasing interest for synergizing cell killing and immune activation to enhance cancer immunotherapy. This review summarizes recent progress in the molecular mechanisms of pyroptosis and highlights emerging nanomedicine strategies designed to precisely induce pyroptosis within tumors. The discussion further extends to design principles, activation modalities, and therapeutic outcomes in preclinical models. Finally, current challenges and future directions toward clinical translation are outlined. Collectively, this review integrates pyroptosis biology with nanoengineering concepts to inspire nextâgeneration immunotherapeutic interventions against cancer.
- 17 August 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15  (35)
PyroptosisâInducing Nanomedicine for Cancer Immunotherapy: Mechanisms and Emerging Strategies
Cancer immunotherapy has revolutionized oncologic treatment, yet its efficacy remains constrained by tumor immune evasion and the immunosuppressive tumor microenvironment. Addressing these multifaceted barriers calls for strategies that can both eliminate cancer cells and simultaneously amplify antitumor immunity. Pyroptosis, a lytic and highly immunogenic form of programmed cell death mediated by gasdermin proteins, has recently emerged as a compelling approach to reprogram the tumor immune landscape. By releasing abundant damageâassociated molecular patterns and proâinflammatory cytokines, pyroptosis not only destroys tumor cells but also promotes antigen presentation and robust localâtoâsystemic immune responses. With the rapid advancement of nanotechnology, pyroptosisâengineered nanomedicine has gained increasing interest for synergizing cell killing and immune activation to enhance cancer immunotherapy. This review summarizes recent progress in the molecular mechanisms of pyroptosis and highlights emerging nanomedicine strategies designed to precisely induce pyroptosis within tumors. The discussion further extends to design principles, activation modalities, and therapeutic outcomes in preclinical models. Finally, current challenges and future directions toward clinical translation are outlined. Collectively, this review integrates pyroptosis biology with nanoengineering concepts to inspire nextâgeneration immunotherapeutic interventions against cancer.
- 5 August 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15  (33)
Engineered Injectable Hydrogel Platform for Tailoring the Osteoarthritis Microenvironment
Osteoarthritis (OA) represents a selfâsustaining degenerative process characterized by maladaptive interactions among the cartilage, bone, and synovium triads, with current palliative treatments falling short of addressing its pathophysiological intricacies. Recently, injectable hydrogels specifically designed to tackle the distinct challenges of OA have emerged as a potential solution, offering significant advantages over traditional therapies through innovative integration. This review offers a comprehensive examination of the latest advancements in injectable hydrogelâbased therapies for managing OA. First, we dissect the molecular and cellular mechanisms that drive OA progression, placing specific attention on microenvironmental dysregulation. Next, we analyze various hydrogel design strategies, such as matrix composition, crosslinking methods, and stimulusâresponsive release, that influence mechanical strength and therapeutic precision. Additionally, we discuss the multifunctional potential of engineered hydrogels, particularly their exceptional ability to support targeted drug delivery. Finally, this review emphasizes the novel potential of these engineered systems to address the unique challenges related to OA management while overcoming the limitations of existing therapies, thereby positioning them as transformative tools for future clinical applications.
- 5 August 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15  (33)
Engineered Injectable Hydrogel Platform for Tailoring the Osteoarthritis Microenvironment
Osteoarthritis (OA) represents a selfâsustaining degenerative process characterized by maladaptive interactions among the cartilage, bone, and synovium triads, with current palliative treatments falling short of addressing its pathophysiological intricacies. Recently, injectable hydrogels specifically designed to tackle the distinct challenges of OA have emerged as a potential solution, offering significant advantages over traditional therapies through innovative integration. This review offers a comprehensive examination of the latest advancements in injectable hydrogelâbased therapies for managing OA. First, we dissect the molecular and cellular mechanisms that drive OA progression, placing specific attention on microenvironmental dysregulation. Next, we analyze various hydrogel design strategies, such as matrix composition, crosslinking methods, and stimulusâresponsive release, that influence mechanical strength and therapeutic precision. Additionally, we discuss the multifunctional potential of engineered hydrogels, particularly their exceptional ability to support targeted drug delivery. Finally, this review emphasizes the novel potential of these engineered systems to address the unique challenges related to OA management while overcoming the limitations of existing therapies, thereby positioning them as transformative tools for future clinical applications.
- 14 July 2026
- Published by Elsevier in Biomaterials
- Vol. 336, 124459
In situ engineering of a self-healing drug-scaffold hydrogel to block platelet-driven postoperative metastasis
- 14 July 2026
- Published by Elsevier in Biomaterials
- Vol. 336, 124459
In situ engineering of a self-healing drug-scaffold hydrogel to block platelet-driven postoperative metastasis
- 13 March 2026
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 26  (11) , 3907-3916
Assembly Module-Empowering Lipid-Prodrug Nanoamplifier for Enhancing Ferroptosis-Driven Cancer Treatment
Ferroptosis has been widely explored as a promising cancer therapeutic target. Conventional ferroptosis induction relies on inhibiting glutathione peroxidase 4 (GPX4) to promote lipid peroxide accumulation. However, its efficacy is often limited by insufficient endogenous unsaturated lipids in tumor cells. To address this limitation, we developed a lipid-prodrug nanoamplifier (SIM-SS-LA NAs), composed of disulfide-linked linoleic alcohol and simvastatin (SIM) to enhance ferroptosis. Significant, the modularity of the prodrug not only promotes the assembly of the SIM but also amplifies its ferroptosis effect. In the highly reductive tumor microenvironment, disulfide bonds are cleaved, releasing SIM and LA. Notably, the released LA acts as an exogenous substrate, substantially increasing lipid peroxide accumulation and synergizing with SIM-mediated GPX4 inhibition to amplify ferroptosis. As expected, the lipid-prodrug nanoamplifier showed potent ferroptosis-driven antitumor activity in a 4T1 breast tumor-bearing mouse model, offering an efficient nanotherapeutic strategy for ferroptosis-based cancer therapy.
- 13 March 2026
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 26  (11) , 3907-3916
Assembly Module-Empowering Lipid-Prodrug Nanoamplifier for Enhancing Ferroptosis-Driven Cancer Treatment
Ferroptosis has been widely explored as a promising cancer therapeutic target. Conventional ferroptosis induction relies on inhibiting glutathione peroxidase 4 (GPX4) to promote lipid peroxide accumulation. However, its efficacy is often limited by insufficient endogenous unsaturated lipids in tumor cells. To address this limitation, we developed a lipid-prodrug nanoamplifier (SIM-SS-LA NAs), composed of disulfide-linked linoleic alcohol and simvastatin (SIM) to enhance ferroptosis. Significant, the modularity of the prodrug not only promotes the assembly of the SIM but also amplifies its ferroptosis effect. In the highly reductive tumor microenvironment, disulfide bonds are cleaved, releasing SIM and LA. Notably, the released LA acts as an exogenous substrate, substantially increasing lipid peroxide accumulation and synergizing with SIM-mediated GPX4 inhibition to amplify ferroptosis. As expected, the lipid-prodrug nanoamplifier showed potent ferroptosis-driven antitumor activity in a 4T1 breast tumor-bearing mouse model, offering an efficient nanotherapeutic strategy for ferroptosis-based cancer therapy.
- 15 December 2025
- Published by American Chemical Society (ACS) in ACS Materials Letters
- Vol. 8  (1) , 249-257
Intelligent Design of Artesunate-like Analogue Nanoassemblies for Optimized Antitumor Efficacy
- 15 December 2025
- Published by American Chemical Society (ACS) in ACS Materials Letters
- Vol. 8  (1) , 249-257
Intelligent Design of Artesunate-like Analogue Nanoassemblies for Optimized Antitumor Efficacy
- Open Access
- 8 November 2025
- Published by Elsevier in Cell Reports Medicine
- Vol. 6  (11) , 102427
Fluorinated prodrug-engineered nano-remodeler relieves tumor hypoxia for dual-enhanced ferroptosis-immunotherapy
- 8 November 2025
- Published by Elsevier in Cell Reports Medicine
- Vol. 6  (11) , 102427
Open AccessFluorinated prodrug-engineered nano-remodeler relieves tumor hypoxia for dual-enhanced ferroptosis-immunotherapy
- 27 October 2025
- Published by Royal Society of Chemistry (RSC) in Materials Horizons
- Vol. 12  (21) , 8895-8919
Nanozyme-enabled cancer theranostics: bridging enzyme mimicry and material intelligence
Nanozymes, an innovative class of biocatalytic nanomaterials, have emerged as transformative tools in cancer theranostics.
- 27 October 2025
- Published by Royal Society of Chemistry (RSC) in Materials Horizons
- Vol. 12  (21) , 8895-8919
Nanozyme-enabled cancer theranostics: bridging enzyme mimicry and material intelligence
Nanozymes, an innovative class of biocatalytic nanomaterials, have emerged as transformative tools in cancer theranostics.
- 4 September 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14  (32) , e01730
NanogelâEngineered Drug Delivery Systems for Enhanced Ocular Therapeutics
Despite the growing global burden of ocular disorders, conventional ophthalmic formulations remain limited by inadequate bioavailability, rapid clearance, and poor corneal penetration, necessitating frequent dosing and compromising efficacy. This review highlights the revolutionary potential of nanogels, which integrate the advantages of nanoparticles and hydrogels, as advanced ocular drug delivery systems. Through structural engineering and advanced preparation techniques, nanogels achieve enhanced corneal retention, superior mucoadhesion, and controlled drug release. The authors systematically evaluate their efficacy across diverse ocular pathologies, from anterior segment diseases to posterior segment conditions, demonstrating improved corneal permeability and therapeutic outcomes. Current translational challenges, including scalable manufacturing and sterilization requirements, are critically discussed. By synthesizing recent advances and barriers, this review provides a roadmap for developing clinically viable nanogelâbased therapeutics, aiming to enhance treatment efficacy while overcoming patient compliance challenges in ocular medicine.
- 4 September 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14  (32) , e01730
NanogelâEngineered Drug Delivery Systems for Enhanced Ocular Therapeutics
Despite the growing global burden of ocular disorders, conventional ophthalmic formulations remain limited by inadequate bioavailability, rapid clearance, and poor corneal penetration, necessitating frequent dosing and compromising efficacy. This review highlights the revolutionary potential of nanogels, which integrate the advantages of nanoparticles and hydrogels, as advanced ocular drug delivery systems. Through structural engineering and advanced preparation techniques, nanogels achieve enhanced corneal retention, superior mucoadhesion, and controlled drug release. The authors systematically evaluate their efficacy across diverse ocular pathologies, from anterior segment diseases to posterior segment conditions, demonstrating improved corneal permeability and therapeutic outcomes. Current translational challenges, including scalable manufacturing and sterilization requirements, are critically discussed. By synthesizing recent advances and barriers, this review provides a roadmap for developing clinically viable nanogelâbased therapeutics, aiming to enhance treatment efficacy while overcoming patient compliance challenges in ocular medicine.